PSORIASIS Y ENFERMEDAD CARDIOVASCULAR: MECANISMOS INMUNOLÓGICOS Y MOLECULARES.

José Manuel Ríos Yuil; Emma Yuil de Ríos

Enviado octubre 20, 2024

Publicado 2026-03-02

Artículos de Investigación

Vol. 24 Núm. 1 (2011): Revista Médico Científica

PSORIASIS Y ENFERMEDAD CARDIOVASCULAR: MECANISMOS INMUNOLÓGICOS Y MOLECULARES.

José Manuel Ríos Yuil ⁺⁻
Emma Yuil de Ríos⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-03-02

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

La psoriasis es una enfermedad inflamatoria crónica sistémica, que está asociada a un aumento en el riesgo de sufrir enfermedad cardiovascular y otras múltiples comorbilidades. En la psoriasis hay elevación de las concentraciones séricas de múltiples citocinas, tales como: factor de necrosis tumoral alfa (TNF-?), interferón gamma, interleucinas 6, 8, 12, 17, 18, entre otras. Las concentraciones elevadas de TNF-? favorecen el desarrollo de síndrome metabólico, diabetes mellitus y enfermedad cardiovascular. Esto ocurre porque el TNF-? genera resistencia a la insulina al interferir con la vía de señalización de la misma. La resistencia a la insulina contribuye a la patogénesis del síndrome metabólico al generar hiperglicemia e hiperinsulinemia compensatoria que favorecen el desarrollo de obesidad, esteatosis hepática, dislipidemia y enfermedad aterosclerótica.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Puig-Sanz L. La sistémica?. Actas Dermosifiliogr 2007; 98: 396-402.
Ejaz A, Raza N, Iftikhar N, Iftikhar A, Farooq M. Presentation of early onset psoriasis in comparison with late onset psoriasis: a clinical study from Pakistan. Ind J Dermatol Venereol Leprol 2009; 75: 36-40.
García Pérez A. Dermatología clínica. Quinta edición. Salamanca, España. Editorial Cervantes. 1997. p. 229, 238, 275-8, 280-1, 406, 541, 579.
Mazzini M. Dermatología clínica. Segunda edición. Buenos Aires, Argentina. López Libreros Editores. 1985. p. 120, 152, 395, 497, 504, 506-7.
Traub M, Marshall K. Psoriasis – Pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007; 12: 319-30.
Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett. 2008; 13: 1-5.
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010; 90: 147-51.
Choi WJ, Park EJ, Kwon IH, Kim KH, Kim KJ. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Derm. 2010; 22: 300-6.
Kaplan M. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc Health Risk Manag. 2008; 4: 1229-35.
Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, Zanon M, Balbi G, Doria A, Punzi L. Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data. Reumatismo. 2009; 61: 298-305.
Soy M, Yildiz M, Sevki Uyanik M, Karaca N, Güfer G, Piskin S. Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid-femoral (aortic) pulse-wave velocity measurement. Rev Esp Cardiol. 2009; 62: 96-9.
Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010; 90: 23-6.
Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007; 167: 1670-5.
Sidiropoulos P, Karvounaris S, Boumpas D. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications. Arthritis Res Ther 2008; 10: 207.
Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Ind J Med Res. 2010; 131: 743-60.
Choi K, Kim YB. Molecular Mechanism of Insulin Resistance in Obesity and Type 2 Diabetes. Korean J Intern Med. 2010 Jun; 25(2): 119-29.
Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res. 2004; 27: 361-70.
Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2005; 19: 1-20.
Nestle FO, Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol. 2004; 123: xiv-xv.
Rios JM. Nuevos conceptos en la fisiopatología de la psoriasis. Revista Medica-CSS 2009; 35(1): 50-56.
Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-?, IFN-?, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients with Active Psoriasis and Correlation with Disease Severity. Mediators Inflamm. 2005; 5: 273-9.
Duarte GV, Follador I, Cavalheiro CMA, Silva TS, Oliveira MFSP. Psoriasis and obesity: literature review and recommendations for management. An Bras Dermatol. 2010; 85: 355-60.
Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010; 7: 284-9.
Rizvi AA. Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome and type 2 diabetes. Chin Med J. 2007; 120: 1918-24.
Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005; 64: 765-6.
Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM. Tumor necrosis factor-? induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006; 99: 69-77.
Plomgaard P, Keller P, Keller C, Pedersen BK. TNF-?, but not IL-6, stimulates plasminogen activator inhibitor expression in human subcutaneous adipose tissue. J Appl Physiol. 2005; 98: 2019-23.
Gwozdziewiczová S, Lichnovská R, Ben Yahia R, Chlup R, Hrebicek J. TNF-? in the development of insulin resistance and other disorders in metabolic syndrome. Biomed Papers. 2005; 149: 109-17.
Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-?B: effects on liver homeostasis and beyond. Endocr Rev. 2007; 28: 365-86.
Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008; 14: 222-31.
Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008; 14: 741-51.
Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002 Jan 11; 277(2): 1531-7.
Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-? induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005 Oct; 54(10): 2939-45.
Friedman JE, Kirwan JP, Jing M, Presley L, Catalano PM. Increased skeletal muscle tumor necrosis factor-? and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum. Diabetes. 2008; 57: 606-13.
Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007; 87: 507-20.

Palabras clave

PDF

Resumen visto - 10 veces
PDF descargado - 1

Licencia

Content Top

[1] Puig-Sanz L. La sistémica?. Actas Dermosifiliogr 2007; 98: 396-402.

[2] Ejaz A, Raza N, Iftikhar N, Iftikhar A, Farooq M. Presentation of early onset psoriasis in comparison with late onset psoriasis: a clinical study from Pakistan. Ind J Dermatol Venereol Leprol 2009; 75: 36-40.

[3] García Pérez A. Dermatología clínica. Quinta edición. Salamanca, España. Editorial Cervantes. 1997. p. 229, 238, 275-8, 280-1, 406, 541, 579.

[4] Mazzini M. Dermatología clínica. Segunda edición. Buenos Aires, Argentina. López Libreros Editores. 1985. p. 120, 152, 395, 497, 504, 506-7.

[5] Traub M, Marshall K. Psoriasis – Pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007; 12: 319-30.

[6] Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett. 2008; 13: 1-5.

[7] Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010; 90: 147-51.

[8] Choi WJ, Park EJ, Kwon IH, Kim KH, Kim KJ. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Derm. 2010; 22: 300-6.

[9] Kaplan M. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc Health Risk Manag. 2008; 4: 1229-35.

[10] Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, Zanon M, Balbi G, Doria A, Punzi L. Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data. Reumatismo. 2009; 61: 298-305.

[11] Soy M, Yildiz M, Sevki Uyanik M, Karaca N, Güfer G, Piskin S. Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid-femoral (aortic) pulse-wave velocity measurement. Rev Esp Cardiol. 2009; 62: 96-9.

[12] Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010; 90: 23-6.

[13] Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007; 167: 1670-5.

[14] Sidiropoulos P, Karvounaris S, Boumpas D. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications. Arthritis Res Ther 2008; 10: 207.

[15] Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Ind J Med Res. 2010; 131: 743-60.

[16] Choi K, Kim YB. Molecular Mechanism of Insulin Resistance in Obesity and Type 2 Diabetes. Korean J Intern Med. 2010 Jun; 25(2): 119-29.

[17] Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res. 2004; 27: 361-70.

[18] Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2005; 19: 1-20.

[19] Nestle FO, Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol. 2004; 123: xiv-xv.

[20] Rios JM. Nuevos conceptos en la fisiopatología de la psoriasis. Revista Medica-CSS 2009; 35(1): 50-56.

[21] Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-?, IFN-?, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients with Active Psoriasis and Correlation with Disease Severity. Mediators Inflamm. 2005; 5: 273-9.

[22] Duarte GV, Follador I, Cavalheiro CMA, Silva TS, Oliveira MFSP. Psoriasis and obesity: literature review and recommendations for management. An Bras Dermatol. 2010; 85: 355-60.

[23] Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010; 7: 284-9.

[24] Rizvi AA. Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome and type 2 diabetes. Chin Med J. 2007; 120: 1918-24.

[25] Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005; 64: 765-6.

[26] Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM. Tumor necrosis factor-? induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006; 99: 69-77.

[27] Plomgaard P, Keller P, Keller C, Pedersen BK. TNF-?, but not IL-6, stimulates plasminogen activator inhibitor expression in human subcutaneous adipose tissue. J Appl Physiol. 2005; 98: 2019-23.

[28] Gwozdziewiczová S, Lichnovská R, Ben Yahia R, Chlup R, Hrebicek J. TNF-? in the development of insulin resistance and other disorders in metabolic syndrome. Biomed Papers. 2005; 149: 109-17.

[29] Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-?B: effects on liver homeostasis and beyond. Endocr Rev. 2007; 28: 365-86.

[30] Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008; 14: 222-31.

[31] Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008; 14: 741-51.

[32] Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002 Jan 11; 277(2): 1531-7.

[33] Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-? induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005 Oct; 54(10): 2939-45.

[34] Friedman JE, Kirwan JP, Jing M, Presley L, Catalano PM. Increased skeletal muscle tumor necrosis factor-? and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum. Diabetes. 2008; 57: 606-13.

[35] Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007; 87: 507-20.

Imagen de portada

Resumen

Descargas

Citas

Palabras clave

Licencia